SYNAIRGEN PLC Logo

SYNAIRGEN PLC

Develops inhaled antiviral therapies for severe respiratory diseases.

SNG | IL

Overview

Corporate Details

ISIN(s):
GB00B0381Z20
LEI:
213800IMMTOPPDF8HD24
Country:
United Kingdom
Address:
MAILPOINT 810 LEVEL F, SO16 6YD SOUTHAMPTON

Description

Synairgen PLC is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe respiratory diseases. The company's primary focus is its lead investigative candidate, SNG001, an inhaled formulation of interferon-beta (IFN-β). SNG001 is being developed as a potential host-directed, broad-spectrum antiviral therapy delivered directly to the lungs. This approach aims to treat hospitalized patients with severe viral lung infections caused by a range of pathogens, including influenza, RSV, and coronaviruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-05 08:00
Board Change
English 11.1 KB
2024-06-27 08:00
2023 Full Year Results
English 129.1 KB
2023-11-15 08:00
Grant of Options
English 28.7 KB
2023-10-11 08:00
Appointment of New Chief Financial Officer
English 17.5 KB
2023-10-03 08:00
Appointment of Chief Medical Officer
English 11.5 KB
2023-09-21 08:00
Interim Results
English 138.6 KB
2023-06-29 19:02
Result of AGM
English 11.0 KB
2023-06-29 11:00
Annual General Meeting Presentation
English 10.6 KB
2023-06-22 08:00
Grant of Options
English 60.3 KB
2023-05-23 08:00
Posting of Annual Report and Notice of AGM
English 12.0 KB
2023-04-27 08:00
2022 Full Year Results
English 132.1 KB
2023-04-17 08:00
Notice of Full Year results
English 10.1 KB
2023-03-13 17:40
Second Price Monitoring Extn
English 2.8 KB
2023-03-13 17:35
Price Monitoring Extension
English 2.8 KB
2023-02-03 17:40
Second Price Monitoring Extn
English 2.8 KB

Automate Your Workflow. Get a real-time feed of all SYNAIRGEN PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SYNAIRGEN PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SYNAIRGEN PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.